MOH — authorised 19 September 2016
- Marketing authorisation holder: SAREPTA THERAPEUTICS INC
- Status: likely_approved
MOH authorised Exondys 51 on 19 September 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 19 September 2016.
SAREPTA THERAPEUTICS INC holds the UAE marketing authorisation.